deferiprone has been researched along with Blood Diseases in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "deferoxamine treatment than combined treatment with deferiprone and deferoxamine." | 2.44 | Light and shadows in the iron chelation treatment of haematological diseases. ( Maggio, A, 2007) |
| " The elimination half-life (elt1/2) of the drug was 91." | 1.29 | Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. ( al-Refaie, FN; Hoffbrand, AV; Nortey, P; Sheppard, LN; Wonke, B, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Porter, JB | 1 |
| Taher, AT | 1 |
| Cappellini, MD | 2 |
| Vichinsky, EP | 1 |
| Hoffbrand, AV | 2 |
| Taher, A | 1 |
| Maggio, A | 1 |
| al-Refaie, FN | 1 |
| Sheppard, LN | 1 |
| Nortey, P | 1 |
| Wonke, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Platelet Changes in Cases of Iron Overload(IO)[NCT04329377] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506] | 50 participants (Anticipated) | Observational | 2022-07-02 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferiprone and Blood Diseases
| Article | Year |
|---|---|
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; | 2007 |
3 other studies available for deferiprone and Blood Diseases
| Article | Year |
|---|---|
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side | 2008 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Deferiprone; Female; Hematologic D | 1995 |